JP2005506340A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005506340A5 JP2005506340A5 JP2003535542A JP2003535542A JP2005506340A5 JP 2005506340 A5 JP2005506340 A5 JP 2005506340A5 JP 2003535542 A JP2003535542 A JP 2003535542A JP 2003535542 A JP2003535542 A JP 2003535542A JP 2005506340 A5 JP2005506340 A5 JP 2005506340A5
- Authority
- JP
- Japan
- Prior art keywords
- therapeutic agent
- targeted therapeutic
- igf
- amino acids
- targeted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32965001P | 2001-10-16 | 2001-10-16 | |
| US10/136,639 US20030072761A1 (en) | 2001-10-16 | 2002-04-30 | Methods and compositions for targeting proteins across the blood brain barrier |
| US10/136,841 US7396811B2 (en) | 2001-04-30 | 2002-04-30 | Subcellular targeting of therapeutic proteins |
| US38445202P | 2002-05-29 | 2002-05-29 | |
| US38601902P | 2002-06-05 | 2002-06-05 | |
| US40881602P | 2002-09-06 | 2002-09-06 | |
| PCT/US2002/032968 WO2003032727A1 (en) | 2001-10-16 | 2002-10-16 | Methods and compositions for targeting underglycosylated proteins across the blood brain barrier |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009143436A Division JP2009203241A (ja) | 2001-10-16 | 2009-06-16 | 血液脳関門をわたる過小グリコシル化タンパク質の標的化のための方法および組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005506340A JP2005506340A (ja) | 2005-03-03 |
| JP2005506340A5 true JP2005506340A5 (enExample) | 2006-01-12 |
Family
ID=27558195
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003535542A Pending JP2005506340A (ja) | 2001-10-16 | 2002-10-16 | 血液脳関門をわたる過小グリコシル化タンパク質の標的化のための方法および組成物 |
| JP2009143436A Pending JP2009203241A (ja) | 2001-10-16 | 2009-06-16 | 血液脳関門をわたる過小グリコシル化タンパク質の標的化のための方法および組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009143436A Pending JP2009203241A (ja) | 2001-10-16 | 2009-06-16 | 血液脳関門をわたる過小グリコシル化タンパク質の標的化のための方法および組成物 |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP1446007A4 (enExample) |
| JP (2) | JP2005506340A (enExample) |
| AU (3) | AU2002347910A1 (enExample) |
| CA (1) | CA2463473A1 (enExample) |
| IL (1) | IL161352A0 (enExample) |
| WO (2) | WO2003032727A1 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7560424B2 (en) | 2001-04-30 | 2009-07-14 | Zystor Therapeutics, Inc. | Targeted therapeutic proteins |
| WO2003102583A1 (en) * | 2002-05-29 | 2003-12-11 | Symbiontics, Inc. | Targeted therapeutic proteins |
| EP1974752B1 (en) | 2001-04-30 | 2012-09-26 | BioMarin Pharmaceutical Inc. | Subcellular targeting of therapeutic proteins |
| US7629309B2 (en) | 2002-05-29 | 2009-12-08 | Zystor Therapeutics, Inc. | Targeted therapeutic proteins |
| US20030072761A1 (en) | 2001-10-16 | 2003-04-17 | Lebowitz Jonathan | Methods and compositions for targeting proteins across the blood brain barrier |
| IL161352A0 (en) * | 2001-10-16 | 2004-09-27 | Symbiontics Inc | Methods and compositions for targeting underglycosylated proteins across the blood brain barrier |
| CA2553955C (en) | 2004-02-10 | 2012-08-28 | Zystor Therapeutics, Inc. | Acid alpha-glucosidase and fragments thereof |
| EP2997976A1 (en) | 2007-07-27 | 2016-03-23 | Armagen Technologies, Inc. | Methods and compositions for increasing alpha-l-iduronidase activity in the cns |
| ES2511844T3 (es) * | 2007-12-21 | 2014-10-23 | F. Hoffmann-La Roche Ag | Formulación de anticuerpo |
| ES2629853T3 (es) | 2008-05-07 | 2017-08-16 | Biomarin Pharmaceutical Inc. | Péptidos de dirección lisosómica y usos de los mismos |
| EP2475376B1 (en) | 2009-06-17 | 2016-03-30 | BioMarin Pharmaceutical Inc. | Formulations for lysosomal enzymes |
| SI2485761T1 (sl) | 2009-10-09 | 2019-05-31 | Armagen, Inc. | Postopki in sestavki za povečanje aktivnosti iduronat-2-sulfataze v CŽS |
| NZ702801A (en) * | 2010-06-25 | 2016-08-26 | Shire Human Genetic Therapies | Treatment of sanfilippo syndrome type b |
| EP2588130B1 (en) | 2010-06-25 | 2016-08-17 | Shire Human Genetic Therapies, Inc. | Cns delivery of therapeutic agents |
| AU2011270670B2 (en) | 2010-06-25 | 2017-01-12 | Takeda Pharmaceutical Company Limited | Methods and compositions for CNS delivery of arylsulfatase A |
| UA115649C2 (uk) | 2010-06-25 | 2017-12-11 | Шае Хюмен Дженетік Терапіс, Інк. | Способи та композиції для доставки до цнс ідуронат-2-сульфатази |
| ES2896060T3 (es) | 2010-06-25 | 2022-02-23 | Shire Human Genetic Therapies | Métodos y composiciones para la administración al SNC de arilsulfatasa A |
| CA2805413A1 (en) | 2010-06-25 | 2011-12-29 | Shire Human Genetic Therapies, Inc. | Methods and compositions for cns delivery of heparan n-sulfatase |
| WO2013078564A2 (en) * | 2011-12-01 | 2013-06-06 | Angiochem Inc. | Targeted lysosomal enzyme compounds |
| WO2013096899A2 (en) | 2011-12-23 | 2013-06-27 | Shire Human Genetic Therapies, Inc. | Stable formulations for cns delivery of arylsulfatase a |
| WO2014026283A1 (en) | 2012-08-14 | 2014-02-20 | Angiochem Inc. | Peptide-dendrimer conjugates and uses thereof |
| LT3115372T (lt) | 2012-11-27 | 2019-06-25 | Biomarin Pharmaceutical Inc. | Tiksliniai terapiniai lizosominio fermento sulieti baltymai ir jų panaudojimas |
| KR20150132332A (ko) | 2013-03-15 | 2015-11-25 | 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 | 저농도 항체 제형 |
| HRP20181507T1 (hr) | 2014-04-01 | 2018-11-16 | Swedish Orphan Biovitrum Ab (Publ) | Modificirana sulfamidaza i njena proizvodnja |
| US10980892B2 (en) | 2015-06-15 | 2021-04-20 | Angiochem Inc. | Methods for the treatment of leptomeningeal carcinomatosis |
| IL261246B2 (en) | 2016-02-24 | 2023-03-01 | Biomarin Pharm Inc | Therapeutic fusion proteins targeting lysosomal enzymes, their formulations and their uses |
| JP7749322B2 (ja) | 2018-04-30 | 2025-10-06 | アミカス セラピューティックス インコーポレイテッド | 遺伝子治療構築物及び使用方法 |
| EA202190999A1 (ru) | 2018-10-10 | 2021-10-15 | Амикус Терапьютикс, Инк. | Композиции на основе полипептидов, стабилизированных с помощью дисульфидной связи, и способы применения |
| US20220002688A1 (en) | 2018-12-20 | 2022-01-06 | Armagen, Inc. | Purification of iduronate-2-sulfatase immunoglobulin fusion protein |
| US20240148866A1 (en) * | 2021-02-11 | 2024-05-09 | Denali Therapeutics Inc. | Anti-transferrin receptor fusion proteins and methods of use thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4801575A (en) * | 1986-07-30 | 1989-01-31 | The Regents Of The University Of California | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
| US5672683A (en) * | 1989-09-07 | 1997-09-30 | Alkermes, Inc. | Transferrin neuropharmaceutical agent fusion protein |
| CA2025907A1 (en) * | 1989-09-21 | 1991-03-22 | Franklin D. Collins | Method of transporting compositions across the blood brain barrier |
| US6472140B1 (en) * | 1997-09-05 | 2002-10-29 | The General Hospital Corporation | α-2- macroglobulin therapies and drug screening methods for Alzheimer's disease. |
| WO2003102583A1 (en) * | 2002-05-29 | 2003-12-11 | Symbiontics, Inc. | Targeted therapeutic proteins |
| EP1974752B1 (en) * | 2001-04-30 | 2012-09-26 | BioMarin Pharmaceutical Inc. | Subcellular targeting of therapeutic proteins |
| IL161352A0 (en) * | 2001-10-16 | 2004-09-27 | Symbiontics Inc | Methods and compositions for targeting underglycosylated proteins across the blood brain barrier |
-
2002
- 2002-10-16 IL IL16135202A patent/IL161352A0/xx unknown
- 2002-10-16 CA CA002463473A patent/CA2463473A1/en not_active Abandoned
- 2002-10-16 AU AU2002347910A patent/AU2002347910A1/en not_active Abandoned
- 2002-10-16 WO PCT/US2002/032968 patent/WO2003032727A1/en not_active Ceased
- 2002-10-16 EP EP02801739A patent/EP1446007A4/en not_active Withdrawn
- 2002-10-16 JP JP2003535542A patent/JP2005506340A/ja active Pending
- 2002-10-16 AU AU2002362930A patent/AU2002362930A2/en not_active Abandoned
- 2002-10-16 WO PCT/US2002/032996 patent/WO2003032913A2/en not_active Ceased
-
2009
- 2009-06-16 JP JP2009143436A patent/JP2009203241A/ja active Pending
-
2010
- 2010-08-25 AU AU2010214643A patent/AU2010214643A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2002043746A3 (en) | Compounds with the biological activity of vasoactive intestinal peptide for the treatment of pulmonary and arteriolar hypertension | |
| ES2327986T3 (es) | Liberacion intranuclear de compuestos dirigida por la proteina de choque termico de 70 kd. | |
| JPH02504279A (ja) | インスリン様成長因子１（ｉｇｆ‐１）または因子２（ｉｇｆ‐２）の類縁ペプチド | |
| DE602004024041D1 (de) | Lösliches hyaluronidase-glycoprotein (shasegp), verfahren zu seiner herstellung, verwendungen und dieses enthaltende pharmazeutische zusammensetzungen | |
| JP2008526749A5 (enExample) | ||
| BG105461A (en) | Modified peptides as therapeutic agents | |
| WO1994023751A1 (de) | Nukleinsäure-transferpeptide und deren verwendung zur einschleusung von nukleinsäuren in eukaryontische zellen | |
| TW200944226A (en) | Biologically active peptides | |
| US20210290539A1 (en) | Engineered hemichannels, engineered vesicles, and uses thereof | |
| AU665046B2 (en) | Molecules for iontophoretic delivery | |
| RU2582247C2 (ru) | Ингибиторы апоптоза и их применение | |
| EP3565573B1 (en) | Pac1 receptor agonists (maxcaps) and uses thereof | |
| ZA200602000B (en) | Albumin-binding derivatives of therapeutic peptides | |
| RU2002130203A (ru) | Пептидные конъюгаты для доставки лекарственного средства | |
| CN1879888B (zh) | 透皮给药增强剂及其使用方法 | |
| BR112020026267A2 (pt) | Lisinas e seus derivados resensibilizam novamente staphylococcus aureus e bactérias gram-positivas aos antibióticos | |
| CA2311648A1 (en) | Ifnar2/ifn complex | |
| WO1998037100A3 (en) | Therapeutic use of the smr1 protein and active derivatives thereof | |
| F Nahhas et al. | Nanoscale pathogens treated with nanomaterial-like peptides: a platform technology appropriate for future pandemics | |
| JP2007506713A (ja) | 例えば、抗血管新生活性を有するペプチドおよび治療におけるその適用 | |
| WO2002058589A3 (en) | Agents and methods for promoting bone growth | |
| AU681891B2 (en) | Medical use of stem bromelain protease | |
| JP2023547889A (ja) | 脊椎融合を治療するための化合物、組成物、および使用の方法 | |
| WO1999002120A3 (en) | Compositions and methods for reversibly increasing permeability of biomembranes | |
| TW201809013A (zh) | 用於藥物遞送之抗體融合蛋白 |